hVIVO PLC
LSE:HVO

Watchlist Manager
hVIVO PLC Logo
hVIVO PLC
LSE:HVO
Watchlist
Price: 22 GBX -3.93% Market Closed
Market Cap: 149.7m GBX
Have any thoughts about
hVIVO PLC?
Write Note

hVIVO PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

hVIVO PLC
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
hVIVO PLC
LSE:HVO
Revenue
ÂŁ64.4m
CAGR 3-Years
22%
CAGR 5-Years
64%
CAGR 10-Years
41%
Oxford Nanopore Technologies PLC
LSE:ONT
Revenue
ÂŁ169.7m
CAGR 3-Years
14%
CAGR 5-Years
39%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Revenue
ÂŁ23.7m
CAGR 3-Years
23%
CAGR 5-Years
18%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Revenue
ÂŁ272k
CAGR 3-Years
-30%
CAGR 5-Years
-40%
CAGR 10-Years
-26%
Ergomed PLC
LSE:ERGO
Revenue
ÂŁ152.1m
CAGR 3-Years
27%
CAGR 5-Years
25%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Revenue
ÂŁ24.7m
CAGR 3-Years
N/A
CAGR 5-Years
28%
CAGR 10-Years
N/A
No Stocks Found

hVIVO PLC
Glance View

Market Cap
149.7m GBX
Industry
Life Sciences Tools & Services

hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

HVO Intrinsic Value
26.83 GBX
Undervaluation 18%
Intrinsic Value
Price

See Also

What is hVIVO PLC's Revenue?
Revenue
64.4m GBP

Based on the financial report for Jun 30, 2024, hVIVO PLC's Revenue amounts to 64.4m GBP.

What is hVIVO PLC's Revenue growth rate?
Revenue CAGR 10Y
41%

Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for hVIVO PLC have been 22% over the past three years , 64% over the past five years , and 41% over the past ten years .

Back to Top